Zusammenfassung
Die hämorrhagische Diathese ist eine Erkrankung des Hämostasesystems mit dem Leitsymptom Blutung. Auslösende Ursache für die Blutungsneigung ist eine angeborene oder erworbene Dysfunktion des Hämostasesystems. Zusammen mit der Blutungsanamnese ist der laboranalytische Nachweis einer Gerinnungsstörung beweisend für das Vorliegen einer hämorrhagischen Diathese. Die Blutungsprophylaxe ist neben der Behandlung von akuten Blutungen ein wesentliches Element in der Therapie der hämorrhagischen Diathese
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Franchini M, Targher G, Lippi G (2007) Prophylaxis in von Willebrand disease. Ann Hematol 86: 699–704
Greaves M, Preston FE (2001) Approach to the bleeding patient. In: Colman RW, Hirsh J, Marder VJ, Clowes AW, George JN (eds.). Hemostasis and Thrombosis — basic principles and clinical practice, 4th ed. Lippincott Williams and Wilkins. pp 783–794
Manco-Johnson MJ, Abshire TC, Shapiro AD et al. (2007) Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 357: 535–544
Rodeghiero F, Tosetto A, Castman G (2007) How to estimate bleeding risk in mild bleeding disorders. J Thromb Haemost 5(Suppl 1): 157–166
Shen YM, Frenkel EP (2007) Acquired platelet dysfunction. Hematol Oncol Clin North Am 21: 647–661
Literatur
Allen DL, Samol J, Benjamin S, Verjee S, Tusold A, Murphy MF (2004) Survey of the use and clinical effectiveness of HPA-1a/5b-negative platelet concentrates in proven or suspected platelet alloimmunization. Transfus Med 14: 409–417
Anasetti C, Rybka W, Sullivan KM, Banaji M, Slichter SJ (1989) Graft-v-host disease is associated with autoimmune-like thrombocytopenia. Blood 73: 1054–1058
Andersen JC (1994) Response of resistant idiopathic thrombocytopenic purpura to pulsed high-dose dexamethason therapy. N Engl J Med 330: 1560–1564
Arnold DM, Dentali F, Crowther MA, Meyer RM, Cook RJ, Sigouin C, Fraser GA, Lim W, Kelton JG (2007) Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 146: 25–33
Ballem PJ, Buskard NA, Decary F, Doubroff P (1987) Post-transfusion purpura secondary to passive transfer of anti-Pl(A1) by blood transfusion. Br J Haematol 66: 113–114
Ballmaier M, Germeshausen M, Schulze H, Cherkaoui K, Lang S, Gaudig A, Krukemeier S, Eilers M, Strauss G, Welte K (2001) c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia. Blood 97: 139–146
Barnes C, Blanchette V, Canning P, Carcao M (2005) Recombinant FVIIa in the management of intracerebral haemorrhage in severe thrombocytopenia unresponsive to platelet-enhancing treatment. Transfus Med 15: 145–150
Benda H, Panzer S, Kiefel V, Mannhalter C, Hinterberger W, Lechner K, Mueller-Eckhardt C (1989) Identification of the target platelet glycoprotein in autoimmune thrombocytopenia occurring after allogeneic bone marrow transplantation. Blut 58: 151–153
Berkowitz RL, Kolb EA, McFarland JG, Wissert M, Primani A, Lesser M, Bussel JB (2006) Parallel randomized trials of risk-based therapy for fetal alloimmune thrombocytopenia. Obstet Gynecol 107: 91–96
Bierling P, Cordonnier C, Fromont P, Rodet M, Tanzer J, Vernant JP, Bracq C, Duedari N (1985) Acquired autoimmune thrombocytopenia after allogeneic bone marrow transplantation. Br J Haematol 59: 643–646
Bierling P, Pignon JM, Kuentz M, Mitjavila MT, Fromont P, Barbu V, Goossens M, Duedari N, Vainchenker W, Vernant JP (1994) Thrombocytopenia after bone marrow transplantation caused by a recipient origin Br(a) allo-antibody: presence of mixed chimerism 3 years after the graft without hematological relapse. Blood 83: 274–279
Bizzarro N, Dianese G (1988) Neonatal alloimmune amegakaryocytosis. Case report. Vox Sang 54: 112–114
Bolton-Maggs PH, Chalmers EA, Collins PW et al. (2006) A review of inherited platelet disorders with guidelines for their management on behalf of the UKHCDO. Br J Haematol 135: 603–633
Bougie DW, Wilker PR, Wuitschick ED, Curtis BR, Malik M, Levine S, Lind RN, Pereira J, Aster RH (2002) Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa. Blood 100: 2071–2076
Boylan B, Chen H, Rathore V et al. (2004) Anti-GPVI-associated ITP: An acquired platelet disorder caused by autoantibody-mediated clearance of the GPVI/FcR(gamma)-chain complex from the human platelet surface. Blood 104: 1350–1355
British Committee for Standards in Haematology, Blood Transfusion Task Force (2003) Guidelines for the use of platelet transfusions. Br J Haematol 122: 10–23
Brunner-Bollinger S, Kiefel V, Horber FF, Nydegger UE, Berchtold P (1997) Antibody studies in a patient with acute thrombocytopenia following infusion of plasma containing anti-Pl(A1). Am J Hematol 56: 119–121
Bussel J, Kaplan C, McFarland J (1991) Recommendations for the evaluation and treatment of neonatal autoimmune and alloimmune thrombocytopenia. Thromb Haemost 65: 631–634
Christiaens GCML, Nieuwenhuis HK, Bussel JB (1997) Comparison of platelet counts in first and second newborns of mothers with immune thrombocytopenic purpura. Obstet Gynecol 90: 546–552
Culic S (2003) Recombinant factor VIIa for refractive haemorrhage in autoimmune idiopathic thrombocytopenic purpura [letter]. Br J Haematol 120: 909–910
Curtis BR, Swyers J, Divgi A, McFarland JG, Aster RH (2002) Thrombocytopenia after second exposure to abciximab is caused by antibodies that recognize abciximab-coated platelets. Blood 99: 2054–2059
d’Apolito M, Zelante L, Savoia A (1998) Molecular basis of Fanconi anemia. Haematologica 83: 533–542
Derry JMJ, Ochs HD, Francke U (1994) Isolation of a novel gene mutated in Wiskott-Aldrich syndrome, Wiskott-Aldrich syndrome protein (WASP). Cell 78: 635–644
Dieleman LA, Brand A, Claas FHJ, van de Keur C, Witvliet M, Giphart MJ (1989) Acquired Zw(a) antigen on Zw(a) negative platelets demonstrated by Western blotting. Br J Haematol 72: 539–542
Frederiksen H, Schmidt K (1999) The incidence of idiopathic thrombocytopenic purpura in adults increases with age. Blood 94: 909–913
Garner SF, Campbell K, Metcalfe P, Keidan J, Huiskes E, Dong JF, Lopez JA, Ouwehand WH (2002) Glycoprotein V: the predominant target antigen in gold-induced autoimmune thrombocytopenia. Blood 100: 344–346
George JN, Woolf SH, Raskob GE et al. (1996) Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 88: 3–40
George JN (2001) Platelet kinetics and pathophysiology of thrombocytopenia. In Colman RW, Hirsh J, Marder VJ, Clowes AW, George JN (eds.) Hemostasis and thrombosis. Basic principles and clinical practice, 4th ed. Philadelphia: Lippincott Williams and Wilkins, pp 576–596
George JN, Chong B, Li X (2006) Drug-induced thrombocytopenia. In Colman EW, Marder VJ, Clowes AW, George JN, Goldhaber SZ (eds.) Hemostasis and thrombosis, 5th ed. Philadelphia: Lippincott Williams and Wilkins, pp 1095–1102
Gerstner JB, Smith MJ, Davis KD, Cimo PL, Aster RH (1979) Posttransfusion purpura: therapeutic failure of Pl(A1)-negative platelet transfusion. Am J Hematol 6: 71–75
Ghevaert C, Campbell K, Walton J, Smith GA, Allen D, Williamson LM, Ouwehand WH, Ranasinghe E (2007) Management and outcome of 200 cases of fetomaternal alloimmune thrombocytopenia. Transfusion 47: 901–910
Greenhalgh KL, Howell RT, Bottani A et al. (2002) Thrombocytopeniaabsent radius syndrome: a clinical genetic study. J Med Genet 39: 876–881
Greinacher A, Kiefel V, Klüter H, Kroll H, Pötzsch B, Riess H (2006) Empfehlungen zur Thrombozytentransfusion der Thrombozyten-Arbeitsgruppe der DGTI, GTH und DGHO. Transfusion Med Hemother 33: 528–543
Hall GW (2001) Kasabach-Merritt syndrome: pathogenesis and management. Br J Haematol 112: 851–862
Hamblin TJ, Naorose Abidi SM, Nee PA, Copplestone A, Mufti GJ, Oscier DG (1985) Successful treatment of post-transfusion purpura with high dose immunoglobulins after lack of response to plasma exchange. Vox Sang 49: 164–167
Harrington WJ, Minnich V, Hollingsworth JW, Moore CV (1951) Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura. J Lab Clin Med 38: 1–10
Joenje H, Patel KJ (2001) The emerging genetic and molecular basis of Fanconi anaemia. Nat Rev Genet 2: 446–457
Jubelirer SJ, Koenig BA, Bates MC (1999) Acute profound thrombocytopenia following C7E3 Fab (Abciximab) therapy: case reports, review of the literature and implications for therapy. Am J Hematol 61: 205–208
Kereiakes DJ, Essell JH, Abbottsmith CW, Broderick TM, Runyon JP (1996) Abciximab-associated profound thrombocytopenia: therapy with immunoglobulin and platelet transfusion. Am J Cardiol 78: 1161–1163
Kiefel V, Freitag E, Kroll H, Santoso S, Mueller-Eckhardt C (1996) Platelet autoantibodies (IgG, IgM, IgA) against glycoproteins IIb/IIIa and Ib/IX in patients with thrombocytopenia. Ann Hematol 72: 280–285
Kiefel V, Schönberner-Richter I, Schilf K (2005) Anti-HPA-1a in a case of post-transfusion purpura: binding to antigen-negative platelets detected by adsorption/elution. Transfus Med 15: 243–247
Kiefel V, Bassler D, Kroll H, Paes B, Giers G, Ditomasso J, Alber H, Berns M, Wiebe B, Quenzel EM, Hoch J, Greinacher A (2006) Antigen-positive platelet transfusion in neonatal alloimmune thrombocytopenia (NAIT). Blood 107: 3761–3763
King KE, Kao KJ, Bray PF, Casella JF, Blakemore K, Callan NA, Kennedy SD, Kickler TS (1996) The role of HLA antibodies in neonatal thrombocytopenia: a prospective study. Tissue Antigens 47: 206–211
King S, Germeshausen M, Strauss G, Welte K, Ballmaier M (2005) Congenital amegakaryocytic thrombocytopenia: a retrospective clinical analysis of 20 patients. Br J Haematol 131: 636–644
Klopocki E, Schulze H, Strauss G et al. (2007) Complex inheritance pattern resembling autosomal recessive inheritance involving a microdeletion in thrombocytopenia-absent radius syndrome. Am J Hum Genet 80: 232–240
Kojouri K, Vesely SK, Terrell DR, George JN (2004) Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood 104: 2623–2634
Kosugi S, Tomiyama Y, Shiraga M, Kashiwagi H, Nakao H, Kanayama Y, Kurata Y, Matzuzawa Y (1994) Cyclic thrombocytopenia associated with IgM anti-GPIIb-IIIa autoantibodies. Br J Haematol 88: 809–815
Kuter DJ (1998) Thrombopoietins and thrombopoiesis: a clinical perspective. Vox Sang 74(Suppl. 2): 75–85
Macher S, Schallmoser K, Staber PB, Neumeister P, Posch U, Lanzer G, Panzer S (2005) Severe thrombocytopenia due to host-derived anti-HPA-1a after non-myeloablative allogeneic haematopoietic stem cell transplantation for multiple myeloma: a case report. Vox Sang 89: 257–260
Menitove JE, Pereira J, Hoffman R, Anderson T, Fried W, Aster RH (1989) Cyclic thrombocytopenia of apparent autoimmune etiology. Blood 73: 1561–1569
Metcalfe P, Watkins N, Robinson J, Marsh SGE (2007) IPD — The Immuno Polymorphism Database 2007. http://www.ebi.ac.uk/ipd/hpa/, accessed July 15th 2007
Meyer O, Kiesewetter H, Hermsen M, Petriedes P, Rose M, Seibt H, Salama A (2006) Replacement of intravenous administration of anti-D by subcutaneous administration in patients with autoimmune thrombocytopenia. Pediatr blood cancer 47: 721–722
Moroi M, Jung SM, Okuma M, Shinmyozu K (1989) A patient with platelets deficient in glycoprotein VI that lack both collagen-induced aggregation and adhesion. J Clin Invest 84: 1440–1445
Morrison FS, Mollison PL (1966) Post-transfusion purpura. N Engl J Med 275: 243–248
Mueller-Eckhardt C, Küenzlen E, Thilo-Körner D, Pralle H (1983) High-dose intravenous immunoglobulin for post-transfusion purpura [letter]. N Engl J Med 308: 287
Mueller-Eckhardt C, Kiefel V (1988) High-dose IgG for post-transfusion purpura — revisited. Blut 57: 163–167
Mueller-Eckhardt C, Kiefel V, Grubert A, Kroll H, Weisheit M, Schmidt S, Mueller-Eckhardt G, Santoso S (1989) 348 cases of suspected neonatal alloimmune thrombocytopenia. Lancet i: 363–366
Mueller-Eckhardt C, Kroll H, Kiefel V (1991) Posttransfusion purpura. In: Kaplan-Gouet C, Schlegel N, Salmon C, McGregor J (eds.) Platelet immunology: fundamental and clinical aspects. Paris: John Libbey Eurotext, pp 249–255
Muller JY, Reznikoff-Etievant MF, Patereau C, Dangu C, Chesnel N (1985) Thrombopénies néo-natales allo-immunes. Étude clinique et biologique de 84 cas. Presse Med 14: 83–86
Murphy MF, Bussel JB (2007) Advances in the management of alloimmune thrombocytopenia. Br J Haematol 136: 366–378
Neylon AJ, Saunders PW, Howard MR, Proctor SJ, Taylor PR (2003) Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population-based cohort of 245 patients. Br J Haematol 122: 966–974
Niessner H, Clemetson KJ, Panzer S, Mueller-Eckhardt C, Santoso S, Bettelheim P (1986) Acquired thrombasthenia due to GP IIb/IIIa-specific autoantibodies. Blood 68: 571–576
Panzer S, Kiefel V, Bartram CR, Haas OA, Hinterberger W, Mueller-Eckhardt C, Lechner K (1989) Immune thrombocytopenia more than a year after allogeneic marrow transplantation due to antibodies against donor platelets with anti-Pl(A1) specificity: evidence for a host-derived immune reaction. Br J Haematol 71: 259–264
Quiquandon I, Fenaux P, Caulier MT, Pagniez D, Huart JJ, Bauters F (1990) Re-evaluation of the role of azathioprine in the treatment of adult chronic idiopathic thrombocytopenic purpura: a report of 53 cases. Br J Haematol 74: 223–228
Reiner A, Gernsheimer T, Slichter SJ (1995) pulse cyclophosphamide therapy for refractory autoimmune thrombocytopenic purpura. Blood 85: 351–358
Rice L, Nichol JL, McMillan R, Roskos LK, Bacile M (2001) Cyclic immune thrombocytopenia responsive to thrombopoietic growth factor therapy. Am J Hematol 68: 210–214
Rios R, Sangro B, Herrero I, Quiroga J, Prieto J (2005) The role of thrombopoietin in the thrombocytopenia of patients with liver cirrhosis. Am J Gastroenterol 100: 1311–1316
Samuels P, Bussel JB, Braitman LE, Tomaski A, Druzin ML, Mennuti MT, Cines DB (1990) Estimation of the risk of thrombocytopenia in the offspring of pregnant women with presumed immune thrombocytopenic purpura. N Engl J Med 323: 229–235
Schell DA, Ganti AK, Levitt R, Potti A (2002) Thrombocytopenia associated with c7E3 Fab (abciximab). Ann Hematol 81: 76–79
Scott EP, Moilan-Bergeland J, Dalmasso AP (1988) Posttransfusion thrombocytopenia associated with passive transfusion of a platelet-specific antibody. Transfusion 28: 73–76
Sharon R, Amar A (1981) Maternal anti-HLA antibodies and neonatal thrombocytopenia. Lancet i: 1313
Shulman NR, Aster RH, Leithner A, Hiller MC (1961) Immunoreactions involving platelets. V. Post-transfusion purpura due to a complement-fixing antibody against a genetically controlled platelet antigen. A proposed mechanism for thrombocytopenia and its relevance in “autoimmunity„. J Clin Invest 40: 1597–1620
Shulman NR, Marder VJ, Weinrach RS (1965) Similarities between known antiplatelet antibodies and the factor responsible for thrombocytopenia in idiopathic purpura. Physiologic, serologic and isotopic studies. Ann NY Acad Sci 124: 499–542
Shulman NR, Jordan JV (1987) Platelet immunology. In: Colman RW, Hirsh J, Marder VJ, Salzman EW (eds.) Hemostasis and thrombosis. Basic principles and practice. Philadelphia: Lippincott, pp 452–529
Stricker RB, Lewis BH, Corash L, Shuman MA (1987) Posttransfusion purpura associated with an autoantibody directed against a previously undefined platelet antigen. Blood 69: 1458–1463
Sugiyama T, Okuma M, Ushikubi F, Sensaki S, Kanaji K, Uchino H (1987) A novel platelet aggregating factor found in a patient with defective collagen-induced platelet aggregation and autoimmune thrombocytopenia. Blood 69: 1712–1720
Sullivan KE, Mullen CA, Blaese RM, Winkelstein JA (1994) A multiinstitutional survey of the Wiskott-Aldrich syndrome. J Pediatr 125: 876–885
Taaning E, Tonnesen F (1999) Pan-reactive platelet antibodies in post-transfusion purpura. Vox Sang 76: 120–123
Tcheng JE, Kereiakes DJ, Lincoff AM et al. (2001) Abciximab readministration: results of the ReoPro Readministration Registry. Circulation 104: 870–875
Tholouli E, Hay CR, O’Gorman P, Makris M (2004) Acquired Glanzmann’s thrombasthenia without thrombocytopenia: a severe acquired autoimmune bleeding disorder. Br J Haematol 127: 209–213
Thompson AA, Nguyen LT (2000) Amegakaryocytic thrombocytopenia and radio-ulnar synostosis are associated with HOXA11 mutation. Nat Genet 26: 397–398
Thompson AA, Woodruff K, Feig SA, Nguyen LT, Schanen NC (2001) Congenital thrombocytopenia and radio-ulnar synostosis: a new familial syndrome. Br J Haematol 113: 866–870
Tomer A, Schreiber AD, McMillan R, Cines DB, Burstein SA, Thiessen AR, Harker LA (1989) Menstrual cyclic thrombocytopenia. Br J Haematol 71: 519–524
von dem Borne AEGK, Pegels JG, van der Stadt RJ, van der Plas-van Dalen CM, Helmerhorst FM (1986) Thrombocytopenia associated with gold therapy: a drug-induced autoimmune disease. Br J Haematol 63: 509–516
Warkentin TE, Smith JW, Hayward CPM, Ali AM, Kelton JG (1992) Thrombocytopenia caused by passive transfusion of anti-glycoprotein Ia/IIa alloantibody (anti-HPA-5b). Blood 79: 2480–2484
West KA, Anderson DR, McAlister VC, Hewlett TJ, Belitsky P, Smith JW, Kelton JG (1999) Alloimmune thrombocytopenia after organ transplantation. N Engl J Med 341: 1504–1507
Williamson LM, Hackett G, Rennie J, Palmer CR, Maciver C, Hadfield R, Hughes D, Jobson S, Ouwehand W (1998) The natural history of fetomaternal alloimmunization to the platelet-specific antigen HPA-1a (Pl(A1), Zw(a) as determined by antenatal screening. Blood 92: 2280–2287
Win N, Peterkin MA, Watson WH (1995) The therapeutic value of HPA-1a negative platelet transfusion in post-transfusion purpura complicated by life threatening haemorrhage. Vox Sang 39: 138–139
Zhu Q, Watanabe C, Liu T, Hollenbaugh D, Blaese RM, Kanner SB, Aruffo A, Ochs HD (1997) Wiskott-Aldrich syndrome/X-linked thrombocytopenia: WASP gene mutations, protein expression, and phenotype. Blood 90: 2680–2689
Literatur
Balduini CL, Iolascon A, Savoia A (2002) Inherited thrombocytopenias: from genes to therapy. Haematologica 87(8): 860–880
Cattaneo M (2006) Disorders of platelet function. Abnormalities of the platelet P2 receptors. Pathophysiol. Haemost Thromb 35(1–2): 10–14
Cattaneo M, Lecchi A, Agati B, Lombardi R et al. (1999) Evaluation of platelet function with the PFA-100 system in patients with congenital defects of platelet secretion. Thromb Res 96(3): 213–217
Dalton SO, Johansen C, Mellemkjaer L, Norgard B et al. (2003) Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study. Arch Intern Med 163(1): 59–64
de Abajo FJ, Rodriguez LA, Montero D (1999) Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study. BMJ 319(7217): 1106–1109
de Meijer A, Vollaard H, de Metz M, Verbruggen B et al. (1999) Meloxicam, 15 mg/day, spares platelet function in healthy volunteers. Clin Pharmacol Ther 66(4): 425–430
Dong F, Li S, Pujol-Moix N, Luban NL et al. (2005) Genotype-phenotype correlation in MYH9-related thrombocytopenia. Br J Haematol 130(4): 620–627
Garcia Rodriguez LA, Cattaruzzi C, Troncon MG, Agostinis L (1998) Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs. Arch Intern Med 158(1): 33–39
Geddis AE, Kaushansky K (2004) Inherited thrombocytopenias: toward a molecular understanding of disorders of platelet production. Curr Opin Pediatr 16(1): 15–22
Goldenberg NA, Jacobson L, Manco-Johnson MJ (2005) Brief communication: duration of platelet dysfunction after a 7-day course of Ibuprofen. Ann Intern Med 142(7): 506–509
Greinacher A (2005a) Spezielle Diagnostik bei Thrombozyopathien. In: Thomas L (eds) Labor und Diagnose: Indikation und Bewertung von Laborbefunden für die medizinische Diagnostik, 6. Aufl. Frankfurt/Main: TH-Books Verlagsgesellschaft mbH; S 919–922
Greinacher A (2005b) Thrombozytendiagnostik. In: Thomas L (eds) Labor und Diagnose: Indikation und Bewertung von Laborbefunden für die medizinische Diagnostik, 6. Aufl. Frankfurt/Main: TH-Books Verlagsgesellschaft mbH; S 907–909
Halperin D, Reber G (2007) Influence of antidepressants on hemostasis. Dialogues. Clin Neurosci 9(1): 47–59
Jackson SC, Sinclair GD, Cloutier S, Duan X, Rand ML, Poon M-C (2009) Montreal platelet syndrome kindred has type 2B von Willebrand disease with the VWF V1316M mutation. Blood 113:3348–3351
Jurk K, Kehrel BE (2007) Inherited and acquired disorders of platelet function. Transfus Med Hemother 34: 6–19
Kojima H, Moroi M, Jung SM, Goto S et al. (2006) Characterization of a patient with glycoprotein (GP) VI deficiency possessing neither anti-GPVI autoantibody nor genetic aberration. J Thromb Haemost 4(11): 2433–2442
Kottke-Marchant K, Powers JB, Brooks L, Kundu S et al. (1999) The effect of antiplatelet drugs, heparin, and preanalytical variables on platelet function detected by the platelet function analyzer (PFA-100). Clin Appl Thromb Hemost 5(2): 122–130
Kunishima S, Matsushita T, Yoshihara T, Nakase Y et al. (2005) First description of somatic mosaicism in MYH9 disorders. Br J Haematol 128(3): 360–365
Lubenow N, Warkentin TE, Greinacher A, Wessel A et al. (2006) Results of a systematic evaluation of treatment outcomes for heparin-induced thrombocytopenia in patients receiving danaparoid, ancrod, and/or coumarin explain the rapid shift in clinical practice during the 1990s. Thromb Res 117(5): 507–515
Madan M, Berkowitz SD, Christie DJ, Jennings LK et al. (2001) Rapid assessment of glycoprotein IIb/IIIa blockade with the platelet function analyzer (PFA-100) during percutaneous coronary intervention. Am Heart J 141(2): 226–233
Maurer-Spurej E, Pittendreigh C, Wu JK (2007) Diagnosing platelet delta-storage pool disease in children by flow cytometry. Am J Clin Pathol 127(4): 626–632
McKay H, Derome F, Haq MA, Whittaker S et al. (2004) Bleeding risks associated with inheritance of the Quebec platelet disorder. Blood 104(1): 159–165
Meijer WE, Heerdink ER, Nolen WA, Herings RM et al. (2004) Association of risk of abnormal bleeding with degree of serotonin reuptake inhibition by antidepressants. Arch Intern Med 164(21): 2367–2370
Moroi M, Jung SM (2004) Platelet glycoprotein VI: its structure and function. Thromb Res 114(4): 221–233
Movig KL, Janssen MW, de Waal MJ, Kabel PJ et al. (2003) Relationship of serotonergic antidepressants and need for blood transfusion in orthopedic surgical patients. Arch Intern Med 163(19): 2354–2358
Nichols KE, Crispino JD, Poncz M, White JG et al. (2000) Familial dyserythropoietic anaemia and thrombocytopenia due to an inherited mutation in GATA1. Nat Genet 24(3): 266–270
Nieuwenhuis HK, Akkerman JW, Sixma JJ (1987) Patients with a prolonged bleeding time and normal aggregation tests may have storage pool deficiency: studies on one hundred six patients. Blood 70(3): 620–623
Noris P, Pecci A, Di Bari F, Di Stazio MT et al. (2004) Application of a diagnostic algorithm for inherited thrombocytopenias to 46 consecutive patients. Haematologica 89(10): 1219–1225
Nurden AT (2006) Glanzmann thrombasthenia. Orphanet. J Rare Dis 1(1): 10
Oury C, Lenaerts T, Peerlinck K, Vermylen J et al. (1999) Congenital deficiency of the phospholipase C coupled platelet P2Y1 receptor leads to a mild bleeding disorder. Thromb Haemost 85(suppl.) 20 [Abstract]
Oury C, Toth-Zsamboki E, Van Geet C, Thys C et al. (2000) A natural dominant negative P2X1 receptor due to deletion of a single amino acid residue. J Biol Chem 275(30): 22611–22614
Ozelo MC, Svirin P, Larina L (2005) Use of recombinant factor VIIa in the management of severe bleeding episodes in patients with Bernard-Soulier syndrome. Ann Hematol 84(12): 816–822
Poon MC, D’Oiron R, Von Depka M, Khair K et al. (2004) Prophylactic and therapeutic recombinant factor VIIa administration to patients with Glanzmann’s thrombasthenia: results of an international survey. J Thromb Haemost 2(7): 1096–1103
Remijn JA, IJsseldijk MJ, Strunk AL, Abbes AP et al. (2007) Novel molecular defect in the platelet ADP receptor P2Y12 of a patient with haemorrhagic diathesis. Clin Chem Lab Med 45(2): 187–189
Selleng K, Lubenow LE, Greinacher A, Warkentin TE (2007) Perioperative management of MYH9 hereditary macrothrombocytopenia (Fechtner syndrome). Eur J Haematol 79(3): 263–268
Seri M, Pecci A, Di Bari F, Cusano R et al. (2003) MYH9-related disease: May-Hegglin anomaly, Sebastian syndrome, Fechtner syndrome, and Epstein syndrome are not distinct entities but represent a variable expression of a single illness. Medicine (Baltimore) 82(3): 203–215
van Walraven C, Mamdani MM, Wells PS, Williams JI (2001) Inhibition of serotonin reuptake by antidepressants and upper gastrointestinal bleeding in elderly patients: retrospective cohort study. BMJ 323(7314): 655–658
Villa A, Notarangelo L, Macchi P, Mantuano E et al. (1995) X-linked thrombocytopenia and Wiskott-Aldrich syndrome are allelic diseases with mutations in the WASP gene. Nat Genet 9(4): 414–417
Zwaal RF, Comfurius P, Bevers EM (2004) Scott syndrome, a bleeding disorder caused by defective scrambling of membrane phospholipids. Biochim. Biophys. Acta 1636(2–3): 119–128
Literatur
Aledort LM, Haschmeyer RH, Pettersson H (1994) A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group. J Intern Med 236: 391–399
Asakai R, Chung DW, Ratnoff OD et al. (1989) Factor XI (plasma thromboplastin antecedent) deficiency in Ashkenazi Jews is a bleeding disorder that can result from three types of point mutations. Proc Natl Acad Sci USA 86: 7667
Asselta R, Duga S, Tenchini ML (2006a) The molecular basis of quantitative fibrinogen disorders. Journal of Thrombosis and Haemostasis 4: 2115–2129
Asselta R, Tenchini ML, Duga S (2006b) Inherited defects of coagulation factor V: the hemorrhagic side. J Thromb Haemost 4: 26–34
Briët E, Bertina RM, van Tilburg NH, Veltkamp JJ (1982) Hemophilia B Leyden: a sex-linked hereditary disorder that improves after puberty. N Engl J Med 306: 788–790
Briet E, Onvlee G (1987) Hip surgery in a patient with severe factor VII deficiency. Haemost 17: 273
Cooper D, Millar D, Wacey A et al. (1997) Inhertied factor VII deficiency: molecular genetics and pathophysiology. Thromb Haemost 78: 151
de Bosch NB, Mosesson MW, Ruiz-Saez A et al. (2002) Inhibition of thrombin generation in plasma by fibrin formation (Antithrombin I). Thromb Haemost 88: 253–258
de Moerloose P, Neerman-Arbez M (2008) Treatment of congenital fibrinogen disorders. Epert Opin Biol Ther 8: 979–992
Fagan K, Wilkinson J, Allen M et al. (1988) The coagulation factor VII regulator is located on 8q23.1. Hum Genet 79; 365
Hancock J, Wieland K, Pugh RE et al. (1991) A molecular genetic study of factor XI deficiency. Blood 77: 1942
Ivaskevicius V, Seitz R, Kohler HP, Schroeder V, Muszbek L, Ariens RA, Seifried E, Oldenburg J; Study Group (2007) International registry on factor XIII deficiency: a basis formed mostly on European data. Thromb Haemost 97: 914–921
Lak M, Keihani M, Elahi F et al. (1999) Bleeding and thrombosis in 55 patients with inherited afibrinogenaemia. Br J Haematol 107: 204–206
Kurachi S, Furukawa M, Salier JP, Wu CT, Wilson EJ, French FS, Kurachi K (1994) Regulatory mechanism of human factor IX gene: protein binding at the Leyden-specific region. Biochemistry 33: 1580–1591. Erratum in: Biochemistry 1995;34: 14270
Manco-Johnson MJ, Abshire TC, Shapiro AD et al. (2007) Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 357: 535–44
Mannucci PM (2008a) Back to the future: a recent history of hemophilia treatment. Haemophilia 14: 10–8
Mannucci PM (2008b) Prophylaxis in congenital coagulation disorders: past, present and future. Blood Transfus 6: 10–18
McVey JH, Boswell E, Mumford AD et al. (2001) Factor VII deficiency and the FVII mutation database. Hum Mutat 17: 3
Oldenburg J, Quenzel EM, Harbrecht U, Fregin A, Kress W, Müller CR, Hertfelder HJ, Schwaab R, Brackmann HH, Hanfland P (1997) Missense mutations at ALA-10 in the factor IX propeptide: an insignificant variant in normal life but a decisive cause of bleeding during oral anticoagulant therapy. Br J Haematol 98: 240–244
Oldenburg J, von Brederlow B, Fregin A et al. (2000) Congenital deficiency of vitamin K dependent coagulation factors in two families presents as a genetic defect of the vitamin K-epoxide-reductasecomplex. Thromb Haemost 84: 937–941
Oldenburg J, Schwaab R (2001) Molecular biology of blood coagulation. Semin Thromb Hemost 27(4): 313–24; review
Perry DG (2002) Factor VII deficiency. Br J Haematol 118: 689
Pfeifer U, Ormanns W, Klineg O (1981) Hepatocellular fibrinogen storage in familial hypofibrinogenemia. Virchows Arch Cell Pathol 36: 247–255
Rost S, Fregin A, Ivaskevicius V et al. (2004) Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 427: 537–541
Tuddenham E, Pemberton S, Cooper D (1995) Inherited FVII deficiency: Genetics and molecular pathology. Thromb Haemost 74: 313
Uemichi T, Liepnicks JJ, Yamada T et al. (1996) A frame shift mutation in the fibrinogen A alpha chain gene in a kindred with renal amyloidosis. Blood 87: 4197–4203
Vos HL (2007) An online database of mutations and polymorphisms in and around the coagulation factor V gene. J Thromb Haemost 5: 185–188
Wehinger H, Kllineg O, Alexandrakis E et al. (1983) Hereditary hypofibrinogenemia with fibrinogen storage in the liver. Eur J Pediatr 141: 109–112
Yang TL, Cui J, Taylor JM et al. (2000) Rescue of fatal neonatal hemorrhage in factor V deficient mice by low level transgene expression. Thromb Haemost 83: 70
Zhang B, Ginsburg D (2004) Familial multiple coagulation factor deficiencies: new biologic insight from rare genetic bleeding disorders. J Thromb Haemost 2(9): 1564–1572
Literatur
Abshire T, Kenet G (2004) Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. J Thromb Haemost 2: 899–909
Aggarwal A, Grewal R, Green RJ (2005) Rituximab for autoimmune haemophilia a proposed treatment algorithm. Haemophilia 11: 13–19
Astermark J, Donfield SM, DiMichele DM, Gringeri A, Gilbert SA, Waters J, Berntorp E; FENOC Study Group (2007) A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA Astermark J, Wang X, Oldenburg J, Berntorp E, Lefvert AK; MIBS Study Group (2007) Polymorphisms in the CTLA-4 gene and inhibitor development in patients with severe hemophilia A. J Thromb Haemost 5: 263–265
Astermark J, Oldenburg J, Pavlova A, Berntorp E, Lefvert AK; MIBS Study Group (2006) Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associatedwith inhibitor development in patients with hemophilia A. Blood 107: 3167–3172
Astermark J, Oldenburg J, Carlson J, Pavlova A, Kavakli K, Berntorp E, Lefvert AK (2006) Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A. Blood 108: 3739–3745
NovoSeven Comparative (FENOC) Study. Blood 109: 546–551
Bundesärztekammer (2008) Querschnitts-Lleitlinien zur Therapie mit Blutkomponenten und Plasmaderivaten. Kapitel 6: Schramm W, Oldenburg J. Faktor VIII-Konzentrate, Faktor VIII / Von Willebrand-Faktor-Konzentrate, Faktor IX-Konzentrate, Ativierte Prothrombin-Komplex-Konzentrate. Köln: Deutscher Ärzte-Verlag, S 158–189
Brackmann HH, Lenk H, Scharrer I, Auerswald G, Kreuz W (1999) German recommendations for immune tolerance therapy in type A haemophiliacs with antibodies. Haemophilia 5: 203–206
Brackmann HH, Oldenburg J, Schwaab R (1996) Immune tolerance for the treatment of factor VIII inhibitors—twenty years’ ‘bonn protocol’. Vox Sang 70Suppl 1:30–5.
Brackmann HH, Gormsen J (1977) Massive factor-VIII infusion in haemophiliac with factor-VIII inhibitor, high responder. Lancet 2: 933
Calvez T, Laurian Y, Goudemand J (2008) Inhibitor incidence with recombinant vs. plasma-derived FVIII in previously untreated patients with severe hemophilia A: homogeneous results from four published observational studies. J Thromb Haemost 6: 390–392
Cohen A, Kessler CM (1996) Acquired inhibitors. Bailleres Clin Hematol 9: 331–354
Collins PW, Hirsch S, Baglin TP et al. (2007) Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors’ Organisation. Blood 109: 1870–1877
Collins PW (2007) Treatment of acquired hemophilia A. J Thromb Haemost 5: 893–900
Delgado J, Jimenez-Yuste V, Hernandez-Navarro F, Villar A (2003) Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors. Br J Haematol 121: 21–35
DiMichele DM, Hoots WK, Pipe SW, Rivard GE, Santagostino E (2007) International workshop on immune tolerance induction: consensus recommendations.Haemophilia 13(Suppl 1): 1–22
DiMichele DM, Kroner BL (2002) The North American Immune Tolerance Registry: practices, outcomes, outcome predictors. Thromb Haemost 87: 52–57
Franchini M, Lippi G (2008) Acquired factor VIII inhibitors. Blood 112: 250–255
Franchini M, Mengoli C, Lippi G, Targher G, Montagnana M, Salvagno GL, Zaffanello M, Cruciani M (2008) Immune tolerance with rituximab in congenital haemophilia with inhibitors: a systematic literature review based on individual patients’ analysis. Haemophilia 14: 903–912
Franchini M, Veneri D, Lippi G, Stenner R (2006) The efficacy of rituximab in the treatment of inhibitor-associated hemostatic disorders. Thromb Haemost 96; 119–125
Freiburghaus C, Berntorp E, Ekman M, Gunnarsson M, Kjellberg B, Nilsson IM (1999) Tolerance induction using the Malm 1982–1995. Haemophilia 5: 32–39
Garvey B (2008) Rituximab in the treatment of autoimmune haematological disorders. Br J Haematol 141: 149–169
Goudemand J, Rothschild C, Demiguel V et al. (2006) FVIII-LFB and Recombinant FVIII study groups. Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Blood 107: 46–51
Goudemand J (2004) Treatment of bleeding episodes occuring in patients with acquired hemophilia with FEIBA: the French experience. Hemophilia 10: abstract PO14
Gouw SC, van der Bom JG, Marijke van den Berg H (2007a) Treatmentrelated risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 109: 4648–54
Gouw SC, van der Bom JG, Auerswald G, Ettinghausen CE, Tedgård U, van den Berg HM (2007b) Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study. Blood 109: 4693–4697
Green D (1971) Suppression of an antibody to factor VIII by a combination of factor VIII and cyclophosphamide. Blood 37: 381–387
Green D, Lechner K (1981) A survey of 215 nonhemophilic patients with inhibitors to factor VIII. Thromb Haemost 45: 200–203
Green D (2006) The management of acquired hemophilia. Haemophilia. 12(suppl 5): 32–36
Green D, Rademaker AW, Briet E (1993) A prospective, randomized trial of prednisone and cyclophosphamide in the treatment of patients with factor VIII autoantibodies. Thromb Haemost 70: 753–757
Hausl C, Ahmad RU, Sasgary M, Doering CB, Lollar P, Richter G, Schwarz HP, Turecek PL, Reipert BM (2005) High-dose factor VIII inhibits factor VIII-specific memory B cells in hemophilia A with factor VIII inhibitors. Blood 106: 3415–22
Hay CR, Baglin TP, Collins PW, Hill FG, Keeling DM (2000) The diagnosis and management of factor VIII and IX inhibitors: a guideline from the UK Haemophilia Centre Doctors’ Organization (UKHCDO). Br J Haematol 111: 78–90
Hay CRM, Negrier C, Ludlam CA (1997) The treatment of bleeding in acquired hemophilia with recombinant factor VIIa: a multicenter study. Thromb Haemost 78: 3–7
Holme PA, Brosstad F, Tjonnfjord GE (2005) Acquired hemophilia: management of bleeds and immune therapy to eradicate autoantibodies. Haemophilia 11: 510–515
Kempton CL, White GC 2nd. (2008) How we treat a hemophilia A patient with a factor VIII inhibitor. Blood Sep 26. [Epub ahead of print]
Knoebl P, Derfler K (1999) Extracorporeal immunoadsorption for the treatment of haemophilic patients with inhibitors to factor VIII or IX. Vox Sang 7(suppl 1): 57–64
Lian EC, Larcada AF, Chiu AY (1989) Combination immunosuppressive therapy after factor VIII infusion for acquired factor VIII inhibitor. Ann Intern Med 110: 774–778
Lorenzo JI, López A, Altisent C, Aznar JA (2001) Incidence of factor VIII inhibitors in severe haemophilia: the importance of patient age. Br J Haematol 113(3): 600–603
Mariani G, Kroner B Immune Tolerance Study Group (ITSG) (2001) Immune tolerance in hemophilia with factor VIII inhibitors: predictors of success. Haematologica 86: 1186–1193
Mauser-Bunschoten EP, Nieuwenhuis HK, Roosendaal G, van den Berg HM (1995) Low-dose immune tolerance induction in hemophilia A patients with inhibitors. Blood 86: 983–988
Mudad R, Kane WH (1993) DDAVP in acquired haemophilia A: case report and review of the literature. Am J Haematol 43: 295–299
Nemes L, Pitlik E (2000) New protocol for immune tolerance induction in acquired hemophilia. Haematologica 85: 64–68
Oldenburg J (2008) Immuntoleranztherapie bei Hämophilie A. Hämostaseologie 28(Suppl 1): S23–S2
Oldenburg J, Ivaskevicius V, Schröder J, Müller CR, Ganguly A (2006) Genetic background and inhibitors in previously untreated or minimally treated young patients with severe haemophilia A treated with sucrose-formulated recombinant factor VIII. Thromb Haemost 95: 903–905
Oldenburg J, Pavlova A (2006) Genetic risk factors for inhibitors to factors VIII and IX. Haemophilia 12: 15–22; review
Oldenburg J, Picard JK, Schwaab R, Brackmann HH, Tuddenham EG, Simpson E (1997) HLA genotype of patients with severe haemophilia A due to intron 22 inversion with and without inhibitors of factor VIII. Thromb Haemost 77: 238–42
Petrovic M, Derom E, Baele G (2000) Cyclosporine treatment of acquired hemophilia due to factor VIII antibodies. Haematologica 85: 895–896
Sallah S (2004) Treatment of acquired haemophilia with factor eight inhibitor bypassing activity. Haemophilia 10: 169–173
Santagostino E, Mancuso ME, Rocino A, Mancuso G, Mazzucconi MG, Tagliaferri A, Messina M, Mannucci PM (2005) Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study. Br J Haematol 130: 422–427
Schwartz RS, Gabriel DA, Aledort LM, Green D, Kessler CM (1995) A prospective study of treatment of acquired (autoimmune) factor VIII inhibitors with high-dose intravenous gammaglobulin. Blood 86: 797–804
Stasi R, Brunetti M, Stipa E, Amadori S (2004) Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia. Blood 103: 4424–4428
Wiestner A, Cho HJ, Asch AS et al. (2002) Rituximab in the treatment of acquired factor VIII inhibitor. Blood 100: 3426–3428
Zeitler H, Ulrich-Merzenich G, Hess L, Konsek E, Unkrig C, Walger P, Vetter H, Brackmann HH (2005) Treatment of acquired hemophilia by the Bonn-Malmo Protocol: documentation of an in vivo immunomodulating concept. Blood 105: 2287–2293
Zeitler H, Ulrich-Merzenich G, Goldmann G, Vidovic N, Brackmann HH, Oldenburg J (2009) The Relevance of the Bleeding Severity in the treatment of Acquired Haemophilia — an update of a single Centre Experience in 67 Patients. Haemophilie [in press]
Literatur
Budde U, Schüler G, Müller N, Egli H, Dent J, Ruggeri ZM, Zimmerman TS (1984) Acquired von Willebrand’s disease in the myeloproliferative syndrome. Blood 64: 981–985
Budde U, Scharf RE, Franke P, Hartmann-Budde K, Dent J, Ruggeri ZM (1993) Elevated platelet count as a cause of abnormal von Willebrand factor multimer distribution in plasma. Blood 82: 749–1757
Budde U, Schneppenheim R, Eikenboom J et al. (2008) Detailed von Willebrand Factor Multimer Analysis in Patients with von Willebrand Disease in the European Study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD). J Thromb Haemost 6: 762–771
Castaman G, Rodeghiero F (1996) Desmopressin and type IIB von Willebrand disease. Hemophilia 2: 73–76
Castaman G, Federici AB, Rodeghiero F, Mannucci PM (2003) Von Willebrand disease in the year 2003: Towards the complete identification of gene defects for correct diagnosis and treatment. Haematologica 88: 94–108
Castaman G, Lethagen S, Federici AB et al. (2008) Response of desmopressin influenced by the genotype and phenotype in type 1 von Willebrand disease: results from the European study MCMDM-1VWD. Blood 111: 3531–3539
Coppes MJ, Zandvoort SWH, Sparling CR, Poon AO, Weitzman S, Blanchette VS (1992) Acquired von Willebrand disease in Wilm’s tumor paients. J Clin Oncol 10: 422–427
Dalton RG, Dewar MS, Savidge GF, Kernoff PBA, Matthews KB, Greaves M, Preston FE (1987) Hypothyroidism as a cause of acquired von Willebrand’s disease. Lancet 8540: 1007–1009
Federici AB, Rand JH, Bucciarelli P, Budde U, van Genderen PJJ, Mohri H, Meyer D, Rodeghiero F, Sadler E (2000) Acquired von Willebrand syndrome: Data from an international registry. Thromb Haemost 84: 345–349
Federici AB, Mazurier C, Berntorp E, Lee CA, Scharrer I, Goudemand J, Lethagen S, Nitu I, Ludwig G, Hilbert L, Mannucci PM (2004) Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: Results of a multicenter European study. Blood 103: 2032–2038
Geisen U, Heilmann C, Beyersdorf F, Bonk C, Berchtold-Herz M, Schlensak C, Zieger B (2008) Non-surgical bleeding in patients with ventricular assist devices could be explained by acquired von willebrand disease. Eur J Cardiothorac Surg Feb 16 (Epub ahead of print)
Gill JC, Wilson AD, Endres-Brooks J, Montgomery RR (1986) Loss of the largest von Willebrand factor multimers from plasma of patients with congenital cardiac defects. Blood 67: 758–761
Goodeve A, Eikenboom J, Castaman G et al (2007) Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD). Blood 109: 112–21
Heyde EC (1958) Gastrointestinal bleeding in aortic stenosis. N Engl J Med 259: 196–201
Lee CA, Hubbard A, Sabin CA et al. (2009) A Scientific standardization committee communication. Diagnostic repertoire for laboratory diagnosis of von Willebrand disease: Results of a blind study in 32 centres wordwide. J Thromb Haemost [submitted]
Mannucci PM, Ruggeri ZM, Pareti FI, Capitanio A (1977) D.D.A.V.P. in haemophilia. Lancet ii:1171–1172
Mannucci PM. (1997) Desmopressin (DDAVP) in the treatment of bleeding disorders. The first 20 years. Blood 90: 2515–2521
Meyer D, Fressinaud E, Hilbert L, Ribba A, Lavergne JM, Mazurier C (2001) Type 2 von Willebrand disease causing defective von Willebrand factor-dependent platelet function. Bailliere’s Clinical Haematology 14: 349–364
Michiels JJ, Budde U, van Genderen PJJ, van der Planken M, van Vliet HHDM, Schroyens W, Berneman Z (2001) Acquired von Willebrand Syndromes: Clinical features, etiology, pathophysiology, classification and management. Best Pract Clin Haematol 14: 401–436
Nichols WL, Hultin MB, James AH et al. (2008) Von willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and blood Institute (NHLBI) Expert Panel report (USA). Haemophilia 14: 171–232
Rodeghiero F, Castaman GC, Dini E (1987) Epidemiological investigation of the prevalence of von Willebrand’s disease. Blood 69: 454–9
Rodeghiero F, Castaman G (2001) Congenital von Willebrand disease type I: definition, phenotypes, clinical and laboratory assesment. Bailliere’s Clinical Haematology 14: 321–335
Rugggeri ZM (1987) Classification of von Willebrand disease. In: Verstraete M, Vermylen J, Lijnen R, Arnout J. Leuven (eds) Thrombosis and Haemostasis. Leuven: Leuven University Press, pp 419–445
Ruggeri ZM (2001) Structure of von Willebrand factor and its function in platelet adhesion and thrombus formation. Bailliere’s Clinical Haematology 14: 257–278
Sadler EJ (1994) A revised classification of von Willebrand disease. Thromb Haemost 71: 520–525
Sadler JE, Budde U, Eikenboom JCJ et al.; Working Party on von Willebrand Disease Classification (2006) Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 4: 2103–2114
Sadler JE, Rodeghiero F (2005) Provisional criteria for the diagnosis of VWD type 1: on behalf of the SSC Subcommittee on von willebrand factor. J Thromb Haemost 3: 775–777
Schneppenheim R, Budde U, Obser T et al. (2001) Expression and characterization of von Willebrand dimerization defects in different types of von Willebrand disease. Blood 97: 2059–2066
Shim K, Anderson PJ, Tuley EA, Wiswall E, Sadler E (2008) Platelet-VWF complexes are preferred substrates of ADAMTS 13under fluid shear stress. Blood 111: 651–657
Simone JV, Cornet JA, Abildgaard CF (1968) Acquired von Willebrand’s syndrome in systemic lupus erythematodes. Blood 31: 806–811
Thiede A, Priesack J, Werwitzke S, Bohlmann K, Oortwijn B, Lenting P, Eisert R, Ganser A, Budde U (2008) Diagnostic workup of patients with acquired von Willebrand syndrome: a retrospective single-centre cohort study. J Thromb Haemost Jan 17 [Epub ahead of print]
Tosetto A, Rodeghiero F, Castaman G et al. (2006) A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). J Thromb Haemost 4: 766–73
Tosetto A, Castaman G, Rodeghiero F (2008) Evidence-based diagnosis of type 1 von Willebrand disease: a Bayes theorem approach. Blood 111: 3998–4003
Veyradier A, Jenkins CSP, Fressinaud E, Meyer D (2000) Acquired von Willebrand syndrome: From pathophysiology to management. Thromb Haemost 84: 175–182
Vincentelli A, Susen S, Le Touneau T, Six I, Fabre O, Juthier F, Bauters A, Decoene C, Goudemand J, Prat A, Jude B (2003) Acquired von Willebrand syndrome in aortic stenosis. N Engl J Med 349: 343–349
von Willebrand EA (1926) Hereditär pseudohemofili. Finska Läk Sällsk Handl 68: 87–112
Literatur
Adelman B, Michelson AD, Loscalzo J et al. (1985) Plasmin effect on platelet-glycoprotein-Ib-von Willebrand factor interactions. Blood 65: 32–40
Agren A, Wiman B, Schulman S (2007) Laboratory evidence of hyperfibrinolysis in association with low plasminogen activator inhibitor type 1 activity. Blood Coagul Fibrinolysis 18: 657–660
Hunt BJ, Segal H (1999) Hyperfibrinolysis. J Clin Pathol 49: 958
Leebeek FWG, Kluft C, Knot EAR et al. (1991) A shift in balance between profibrinolytic and antifibrinolytic factors causes enhanced fibrinolysis in cirrhosis. Gastroenterology 101: 1382–1390
Mannucci PM (1998) Hemostatic drugs. N Engl J Med 339: 245–253
Molenaar IQ, Warnaar N, Groen H et al. (2007) Efficacy and safety of antifibrinolytic drugs in liver transplantation: a systematic review and meta-analysis. Am J Transplant 7: 185–194
Prisco D, Conti AA, Giurlan L, Falciani M (1998) Clinical application fo fibrinolysis laboratory tests: a review. Ann Ital Med Int 13: 81–87
Van Slyck EJ, Raman SB, Janakiraman N (1989) Primary fibrinolysis in acute monocytic leukemia. Henry Ford Hosp Med J 37: 33–36
Literatur
Abdalla SA, Letarte M (2006) Hereditary hameorrhagic telangiectasia: current views on genetics and mechanism of disease. J Med Genet 43: 97–110
Cheifetz S, Bellon T, Cales C, Vera S, Bernabeu C, Massague J, Letarte M (1992) Endoglin is a component of the transforming growth factorbeta receptor system in human endothelial cells. J Biol Chem 267: 19027–19030
Cole S, Begbie M, Wallace G, Shovlin C (2005) A new locus for hereditary haemorrhagic telangiectasia (HHT3) maps to chromosome 5. J Med Genet 42: 577–582
Dahlgren LS, Effer SB, McGillivray BC, Pugash DJ (2006) Pregnancy with uterine vascular malformations associated with hemorrhagic hereditary telangiectasia: a case report. J Obstet Gynaecol Can 28:720–723
De Cillis E, Burdi N, Bortone AS, D’Agostino D, Fiore T, Ettorre GC, Resta M (2006) Endovascular treatment of pulmonary and cerebral arteriovenous malformations in patients affected by hereditary haemorrhagic teleangiectasia. Curr Pharm Des 12(10):1243–8
Easey AJ, Wallace GM, Hughes JM, Jackson JE, Taylor WJ, Shovlin CL (2003) Should asymptomatic patients with hereditary haemorrhagic telangiectasia (HHT) be screened for zerebral vascular malformations? Data from 22,061 years of HHT patient life. J. Neurol. Neurosurg. Psychiatr 74: 743–748
Faughnan ME, Lui YW, Wirth JA, Pugash RA, Redelmeier DA, Hyland RH, White RI Jr. (2000) Diffuse pulmonary arteriovenous malformations: characteristics and prognosis. Chest 117: 31–8
Fernandez-Lopez A, Sanz-Rodriguez F, Blanco FJ, Bernabeu C, Botella LM (2006) Hereditary hemorrhagic telangiectasia, a vascular dysplasia affecting the TGF-beta signaling pathway. Clin Med Res 4: 66–78
Fulbright RK, Chaloupka JC, Putman CM, Sze GK, Merriam MM, Lee GK, Fayad PB, Awad IA, White RI Jr. (1998) MR of hereditary hemorrhagic telangiectasia: prevalence and spectrum of cerebrovascular malformations. AJNR Am J Neuroradiol 19: 477–484
Gallione CJ, Richards JA, Letteboer TGW et al. (2006) SMAD4 mutations found in unselected HHT patients. J Med Genet 43: 793–793
Gallione CJ, Repetto GM, Legius E et al. (2004) A syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4). Lancet 363: 852–859
Garcia-Tsao G, Korzenik JR, Young L, Henderson KJ, Jain D, Byrd B, Pollak JS, White RI Jr. (2000) Liver disease in patients with hereditary hemorrhagic telangiectasia. N Engl J Med 343: 931–936
Goumans MJ, Valdimarsdottir G, Itoh S, Rosendahl A, Sideras P, ten Dijke P (2002) Balancing the activation state of the endothelium via two distinct TGF-β type I receptors. EMBO J 21: 1743–1753
Guttmacher AE, Marchuk DA, White RI (1995) Hereditary hemorrhagic telangiectasia. NEJM 333: 918–924
Hanes FM (1909) Multiple hereditary telangiectases causing hemorrhage (hereditary hemorrhagic telangiectasia). Bull Johns Hopkins Hosp 20: 63–73
Hsi DH, Ryan GF, Hellems SO, Cheeran DC, Sheils LA (2003) Large aneurysms of the ascending aorta and major coronary arteries in a patient with hereditary hemorrhagic telangiectasia. Mayo Clin Proc 78: 774–776
Ianora AA, Memeo M, Sabba C, Cirulli A, Rotondo A, Angelelli G (2004) Hereditary hemorrhagic telangiectasia: multi-detector row helical CT assessment of hepatic involvement. Radiology 230: 250–259
Jerkic M, Rivas-Elena JV, Santibanez JF, Prieto M, Rodriguez-Barbero A, Perez-Barriocanal F, Pericacho M, Arevalo M, Vary CPH, Letarte M, Bernabeu C, Lopez-Novoa JM (2006) Endoglin regulates cyclooxygenase-2 expression and activity. Circ Res 99: 248–256
Johnson DW, Berg JN, Baldwin MA et al. (1996) Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat Genet 13: 189–195
Knox FA, Frazer DG (2004) Ophthalmic presentation of hereditary haemorrhagic telangiectasia. Eye 18: 947–949
Koleva RI, Conley BA, Romero D, Riley KS, Marto JA, Lux A, Vary CPH (2006) Endoglin structure and function. Determinants of endoglin phosphorylation by transforming growth factor-β receptors. J Biolog Chem 281: 25110–25123
Lande A, Bedford A, Schechter LS (1976) The spectrum of arteriographic findings in Osler-Weber-Rendu disease. Angiology 27: 223–240
Lee DW, White RI Jr, Egglin TK, Pollak JS, Fayad PB, Wirth JA, Rosenblatt MM, Dickey KW, Burdge CM (1997) Embolotherapy of large pulmonary arteriovenous malformations: long-term results. Ann Thorac Surg 64: 930–940
Lenato GM, Lastella P, Di Giacomo MC, Resta N, Suppressa P, Pasculli G, Sabba C, Guanti G (2006) DHPLC-based mutation analysis of ENG and ALK-1 genes in HHT Italian population. Hum Mutat Feb 27: 213–214
Lenato GM, Guanti G (2006) Hereditary haemorrhagic telangiectasia (HHT): genetic and molecular aspects. Curr Pharm Des 12: 1173–1193
Letteboer TG, Zewald RA, Kamping EJ et al. (2005) Hereditary hemorrhagic telangiectasia: ENG and ALK-1 mutations in Dutch patients. Hum Genet 116: 8–16
Lund VJ, Howard DJ (1999) A treatment algorithm for the management of epistaxis in hereditary hemorrhagic telangiectasia. Am J Rhinol 13: 319–322
Mager JJ, Westermann CJ (2000) Value of capillary microscopy in the diagnosis of hereditary hemorrhagic telangiectasia. Arch Dermatol 136: 732–734
McAllister KA, Grogg KM, Johnson DW et al. (1998) Liver failure caused by hepatic angiodysplasia in hereditary hemorrhagic telangiectasia. Am J Gastroenterol 93: 471–473
Osler W (1901) On family form of recurring epistaxis, associated with multiple telangiectases of skin and mucous membranes. Bull Johns Hopkins Hosp 12: 333–337
Oxhoj H, Kjeldsen AD, Nielsen G (2000) Screening for pulmonary arteriovenous malformations: contrast echocardiography versus pulse oximetry. Scand Cardiovasc J 34: 281–5
Plauchu H, de Chadarevian JP, Bideau A, Robert JM (1989) Age-related clinical profile of hereditary hemorrhagic telangiectasia in an epidemiologically recruited population. Am J Med Genet 32: 291–297
Porteous ME, Burn J, Proctor SJ (1992) Hereditary hemorrhagic telangiectasia: a clinical analysis. J Med Genet 29: 527–530
Press OW, Ramsey PG (1984) Entral nervous system infections assocated with hereditary hemorrhagic telangiectasia. Am J Med 77: 86–92
Prigoda NL, Savas S, Abdalla SA, Piovesan B, Rushlow D, Vandezande K, Zhang E, Ozcelik H, Gallie BL, Letarte M (2006) Hereditary haemorrhagic telangiectasia: mutation detection, test sensitivity and novel mutations. J Med Genet 43: 722–728
Reilly PJ, Nostrant TT (1984) Clinical manifestations of hereditary hemorrhagic telangiectasia. Am J Gastroenterol 79: 363–367
Remy J, Remy-Jardin M, Wattinne L, Deffontaines C (1992) Pulmonary arteriovenous malformations: evaluation with CT of the chest before and after treatment. Radiology 182: 809–816
Rendu HJLM (1896) Épistaxis répétées chez un sujet porteur de petits angiomes cutanés et muqueux. Bull Soc Med Hop 13: 731–733
Römer W, Burk M, Schneider W (1992) Hereditäre hämorrhagische Teleangiektasie (Morbus Osler). Dtsch Med Wochenschr 117: 669–675
Sabba C, Pasculli G, Lenato GM, Suppressa P, Lastella P, Memeo M, Dicuonzo F, Guanti G (2007) Hereditary hemorrhagic telangiectasia: clinical features in ENG and ALK1 mutation carriers. J Thromb Haemost 5: 1149–1157
Sabba C (2005) A rare and misdiagnosed bleeding disorder: hereditary hemorrhagic telangiectasia. J Thromb Haemost 3: 2201–2210
Sabba C, Gallitelli M, Palasciano G (2001) Efficacy of unusually high doses of tranexamic acid for the treatment of epistaxis in hereditary hemorrhagic telangiectasia. N Engl J Med 345: 926
Sadick H, Sadick M, Götte K, Naim R, Riedel F, Bran G, Hörmann K (2006) Hereditary hemorrhagic telangiectasia: an update on clinical manifestations and diagnosis measures. Wien Klin Wochenschr 118: 72–80
Scelzo C, Greco S, Bonanni L, Di Cocco P, D’Angelo M, Laurenzi C, Pisani F, Famulari A, Orlando G (2007) The role of liver transplantation in the treatment of hereditary hemorrhagic telangiectasia: a short literature review. Transplant Proc 39: 2045–2047
Shovlin CL, Guttmacher AE, Buscarini E, Faughnan ME, Hyland RH, Westermann CJJ, Kjeldsen AD, Plauchu H (2000) Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet 91: 66–67
Shovlin CL, Winstock AR, Peters AM, Jackson JE, Hughes JM (1995) Medical complications of pregnancy in hereditary haemorrhagic telangiectasia. QJM 88: 879–887
Toporsian M, Gros R, Kabir MG, Vera S, Govindaraju K, Eidelman DH, Husain M, Letarte M (2005) A role for endoglin in coupling eNOS activity and regulating vascular tone revealed in hereditary hemorrhagic telangiectasia. Circ Res 96: 684–692
Trembath RC, Thomson JR, Machado RD et al. (2001) Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. New Engl J Med 345: 325–443
Van Cutsem E, Rutgeerts P, Vantrappen G (1990) Treatment of bleeding gastrointestinal vascular malformations with oestrogen-progesterone. Lancet 335: 953–955
Vase P, Grove O (1986) Gastrointestinal lesions in hereditary hemorrhagic telangiectasia. Gastroenterology 91: 1079–1083
Vase P, Holm M, Arendrup H (1985) Pulmonary arteriovenous fistulas in hereditary hemorrhagic telangiectasia. Acta Med Scand 218: 105–109
Wallace GM, Shovlin CL (2000) A hereditary haemorrhagic telangiectasia family with pulmonary involvement is unlinked to the known HHT genes, endoglin and ALK-1. Thorax 55: 685–690
Weber EP (1907) Multiple hereditary developmental angiomata (telangiectasia) of the skin and mucous membranes associated with recurring hemorrhages. Lancet 2: 160–162
Westermann CJ, Rosina AF, De Vries V, de Coteau PA (2003) The prevalence and manifestations of hereditary haemorrhagic telangiectasia in the afro-caribbean population of the Netherlands Antilles: a family screening. Am J Med Genet 116: 324–328
Westermann CJJ, Porteous ME, Guttmacher AE, Letarte M, Marchuk DA (1994) Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet 8: 345–351
Whiting JH Jr, Korzenik JR, Miller FJ Jr, Pollack JS, White RI Jr. (2000) Fatal outcome after embolotherapy for hepatic arteriovenous malformations of the liver in two patients with hereditary hemorrhagic telangiectasia. J Vasc Interv Radiol 11: 855–858
Zawel L, Dai JL, Buckhaults P, Zhou S, Kinzler KW, Vogelstein B, Kern SE (1998) Human Smad3 and Smad4 are sequence-specific transcription activators. Mol Cell 1: 611–617
Ziani M, Valignat C, Lopez JG, Ruffion A, Plauchu H, Perrin P (2000) Renal arteriovenous malformation requiring surgery in Rendu-Osler-Weber disease (hereditary hemorrhagic telangiectasia). J Urol 164: 1292–1293
Literatur
Agarwal S, Senzolo M, Melikian C et al. (2008) The prevalence of a heparin-like effect shown on the thrombelastograph in patients undergoing liver transplantation. Liver Transpl 14: 855–860
Blonski W, Siropaides T, Reddy KR (2007) Coagulopathy in liver disease. Curr Treat Options Gastroenterol 10: 464–473
Bluff JE, Brown NJ, Reed MW et al. (2008) Tissue factor, angiogenesis and tumor progression. Breast Cancer Res 204. Epub 2008 Mar 17
Caldwell SH, Hoffman M, Lisman T et al. (2006) Coagulation disorders and haemostasis in liver disease: pathophysiology and critical assessment of current management. Hepatology 44: 1039–1046
Chew HK, Wun T, Harvey D et al. (2006) Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 166: 458–464
Ferguson JW, Helmy A, Ludlam C et al. (2008) Hyperfibrinolysis in alcoholic cirrhosis: relative plasminogen activator inhibitor type 1 deficiency. Thromb Res 121: 675–680
Ho SJ, Gemmell R, Brighton TA (2008) Platelet function testing in uraemic patients. Hematology 13: 49–58
Kang Y (1997) Coagulation and liver transplantation: current concepts. Liver Transpl Surg 3: 465–467
Koseki M, Asada N, Uryu H et al. (2007) Successful combined use of tranexamic acid and unfractionated heparin for life-threatening bleeding associated with intravascular coagulation in a patient with chronic myelogenous leukemia in blast crisis. Int J Hematol 86: 403–406
Lisman T, Leebeek FW (2007) Hemostatic alterations in liver disease: a review on pathophysiology, clinical consequences, and treatment. Dig Surg 24: 250–258
Molenaar IQ, Warnaar N, Groen H et al. (2007) Efficacy and safety of antifibrinolytic drugs in liver transplantation: a systematic review and meta-analysis. American Journal of Transplantation 7: 185–194
Molino D, De Lucia D, Gaspare de Santo N (2006) Coagulation disorders in uremia. Semin Nephrol 26: 46–51
Nadir Y, Katz T, Sarig G et al. (2005) Hemostatic balance on the surface of leukemic cells: the role of tissue factor and urokinase plasminogen activator receptor. Haematologica 90: 1549–1556
Schmidt KG, Rasmussen J, Bekker C et al. (1985) Kinetics and in vitro distribution of indium-III-labeled autologous platelets in chronic hepatic disease: mechanisms of thrombocytopenia. Scand J Haematol 34: 39
Senzolo M, Burra P, Cholongitas E et al. (2006) New insights into the coagulopathy of liver disease and liver transplantation. World J Gastroenterol 12: 7725–7736
Thachil J (2008) Relevance of clotting tests in liver disease. Postgrad Med J 84: 177–181
Uchiumi H, Matsushima T, Yamane A et al. (2007) Prevalence and clinical characteristics of acute myeloid leukemia associated with disseminated intravascular coagulation. Int J Hematol 86: 137–142
Vincent JL, Piagnerrelli M (2008) Acute renal failure in the intensive care unit: which technique of renal replacement therapy? Rev Med Brux 29: S9–13
Zuckerman GR, Cornette GL, Clouse RE, Harter HR (1985) Upper gastrointestinal bleeding in patients with chronic renal failure. Ann Intern Med 102: 588–92
Literatur
Brohi K, Cohen MJ, Davenport RA (2007) Acute coagulopathy of trauma: mechanism, identification and effect. Current Opinion in Critical Care 13: 680–685
deJonge E, Levi M, Berends F (1998) Impaired haemostasis by intravenous administration of a gelatin-based plasma expander in human subjects. Thromb Haemost 79: 286–290
Fries D, Streif W, Klingler A et al. (2006) The effect of fibrinogen substitution reversal of dilutional coagulopathy: a case report serial and an in-vitro model. Anesth Analg 102: 347–51
Fries D, Innerhofer P, Klingler A, Berresheim U, Mittermayr M, Calatzis A, Schobersberger W (2002) The effect of the combined administration of colloids and lactated Ringer’s solution on the coagulation system: an in vitro study using thrombelastograph coagulation analysis (ROTEG). Anesth Analg 94(5): 1280–7
Hardy JF, de Moerloose P, Samama CM (2006) Massive transfusion and coagulopathy: pathophysiology and implications for clinical management. Can J Anaesth 53: S40–58
Hiippala ST (1995) Dextran and hydroxyethyl starch interfere with fibrinogen assays. Blood Coagulation and Fibrinolysis 6: 743–746.
Hiippala ST, Myllylä GJ, Vahtera EM (1995) Hemostatic factors and replacement of major blood loss with plasma poor red cell concentrates. Anesth Analg 81: 360–365
Kozek-Langenecker SA (2005) Effects of hydroxyethyl starch solutions on hemostasis. Anesthesiol 103: 654–660
Kozek-Langenecker S (2007) Management of massive operative blood loss. Minerva Anesthesiol 73: 1–15
Levy J (2006) Massive transfusion coagulopathy. Semin Hematol 43: S59–S63
Levi M, de Jonge E (2007) Clinical relevance of the effects of plasma expanders on coagulation. Semin Thromb Hemost 33: 810–815
Petroianu GA, Maleck WH, Koettner KP et al. (2003) Effect of in vitro hemodilution with hydroxyethyl-starch and dextrans on the activity of plasma clotting factors. Crit Care Med 31: 250–254
Ruttmann TG, James MFM, Aronson I (1998) In vivo investigation into the effects of heamodilution with hydroxyethyl starch (200/0.5) and normal saline on coagulation. Brit J Anaesth 80: 612–616
Singbartl K, Innerhofer P, Radvan J et al. (2003) Hemostasis and hemodilution — quantitative-methematical guide for clinical practice. Anesth Analg 96: 929–935
Valeri CR, Cassidy G, Pivacek LE et al. (2001) Anemia induced increase in bleeding time: the implication for treatment of nonsurgical blood loss. Transfusion 41: 977–983
Wilder DM, Reid TJ, Bakaltcheva IB (2002) Hypertonic resuscitation and blood coagulation. Thromb Res 107: 255–261
Literatur
Bagot M, Bagot JL, Besserman O, Bertrand JC (1984) The Gardner-Diamond syndrome or painful recurrent ecchymotic purpura. Rev Stomatol Chir Maxillofac 85: 66–9
Bernard GR, Vincent JL, Laterre PF et al. (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344: 699–709
Beyth RJ, Quinn LM, Landefeld CS (1998) Prospective evaluation of an index for predicting risk of major bleeding in outpatients treated with warfarin. Am J Med 105: 91–99
Chimowitz MI, Lynn MJ, Howlett-Smith H et al. (2005) Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med 352: 1305–1316
Connolly S, Pogue J, Hart R et al. (2006) Clopidogrel plus aspirin versus oral anticoagulation for artrial fibrillation in the atrial fibrillation clopidogrel trial with irbestan for prevention of vascular events (ACTIVE W): a randomised controlled trial. Lancet 367: 1903–1912
Eriksson BI, Lassen MR (2003) Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study. Arch Intern Med 163: 1337–1342
Fibrinolytic therapy trialists (FTT) collaborative group (1994) Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 343: 311–322
Holoubek JE, Holoubek AB (1996) Blood, sweat and fear. “Aclassification of hematidrosis„. J Med 27: 115–133
Hylek EM, Singer DE. Risk factor for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 1994 120: 897–902
Kearon C, Gent M, Hirsh J et al. (1999) Extended anticoagulation compared to placebo after three months of therapy for a first episode of idiopathic venous thromboembolism. N Engl J Med 340: 901–907
Landefeld CS, Beyth RJ (1993) Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med 95: 315–328
Niewenhuis HK, Albada J, Banga JD et al. (1991) Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin and low molecular weight heparin. Blood 78: 2337–2343
Palareti G, Leali N, Coccheri S et al. (1996) Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective, collaborative study (ISCOAT). Lancet 348: 423–428
Schulman S, Elbazi R, Zondag M, O’Donnell M (2008) Clinical factors influencing normalization of prothrombin time after stopping warfarin: a retrospective cohort study. Thromb J 16(6): 15
Shireman TI, Mahnken JD, Howard PA, Kresowik TF, Hou Q, Ellerbeck EF (2006) Development of a contemporary bleeding risk model for elderly warfarin recipients. Chest 130: 1390–6
Sorenson RU, Newman AJ, Gordon EM (1985) Psychogenic purpura in adolescent patients. Clin Pediatr 24: 700–704
The European Atrial Fibrillation Trial Study Group (1995) Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. N Engl J Med 6: 5–10
Verstraete M (1991) Psychogenic hemorrhages. Verh K Acad Geneeskd Belg 53: 5–28
Wells PS, Forgic MA, Simms MS et al. (2003) The outpatient bleeding risk index — validation of a tool for predicting bleeding rates in patients treated for deep venous thrombosis and pulmonary embolism. Arch Intern Med 163: 917–920
Yan AT, Yan RT, Huynh T et al. (2008) Bleeding and outcome in acute coronary syndrome: insights from continuous electrocardiogram monitoring in the integrilin and enoxaparin randomized assessment of acute coronary syndrome treatment (INTERACT) trial. Am Heart J 156: 769–775
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Pötzsch, B. et al. (2010). Hämorrhagische Diathesen. In: Pötzsch, B., Madlener, K. (eds) Hämostaseologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-01544-1_31
Download citation
DOI: https://doi.org/10.1007/978-3-642-01544-1_31
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-01543-4
Online ISBN: 978-3-642-01544-1
eBook Packages: Medicine (German Language)